All In Biotech

NDA 214907 · On Target Labs

Cytalux

Pafolacianine Sodium · Intravenous

NovelPriority reviewOrphan

CDER novel approval, Nov 29, 2021: To help identify ovarian cancer lesions

Last checked: Nov 19, 2026Latest source record: Dec 16, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Nov 29, 2021

Approved uses

2

Original approval plus efficacy supplements

Registered trials

16

3 Phase 3, 6 recruiting

FAERS reports

63

13 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 1, 2026.

1. INDICATIONS AND USAGE CYTALUX is indicated as an adjunct for intraoperative identification of: Malignant lesions in adult patients with ovarian cancer. Malignant and non-malignant pulmonary lesions in adult patients with known or suspected cancer in the lung. CYTALUX is an optical imaging agent indicated as an adjunct for intraoperative identification of: Malignant lesions in adult patients with ovarian cancer. Malignant and non-malignant pulmonary lesions in adult patients with known or suspected cancer in the lung. ( 1 )

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 16, 2022 Supplement 2 · Efficacy · priority review LabelLetter
  • Nov 29, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
1 products under this application
  • CYTALUX · PAFOLACIANINE SODIUM EQ 3.2MG BASE/1.6ML (EQ 2MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pafolacianine" as an intervention, any sponsor and status, largest first.

All 16 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea35
  • vomiting20
  • pruritus7
  • dyspnoea6
  • chest discomfort5
  • drug effect less than expected4
  • flushing4
  • wheezing4
  • false positive investigation result3
  • hyperhidrosis3
  • abdominal pain2
  • chest pain2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20232
202424
202519
202618

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5 on PubMed

Sponsor: On Target Labs

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.